Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation

Experimental Hematology

Volumn 31, Issue 10, 2003, Pages 924-933

  Wu, Catherine J ^a,b,c   Hochberg, Ephraim P ^a,b   Rogers, Shelby A ^a   Kutok, Jeffery L ^b   Biernacki, Melinda ^a   Nascimento, Alessandra F ^b   Marks, Peter ^a,b   Bridges, Kenneth ^b   Ritz, Jerome ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLOBIN; DNA; MESSENGER RNA;

ACCURACY; ALLOGRAFT; ANALYTIC METHOD; ARTICLE; CELL LINEAGE; CELL MUTANT; CHIMERA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DONOR; ELECTROPHORESIS; ERYTHROID CELL; ERYTHROPOIESIS; HUMAN; HUMAN CELL; LEUKOCYTE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SICKLE CELL; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL TRANSPLANTATION; TANDEM REPEAT;

EID: 0141484484     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(03)00227-3     Document Type: Article

References (32)

1. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-vs-leukemia without myeloablative therapy. Blood. 89:1997;4531-4536.
2. Khouri I.F., Keating M., Korbling M., et al. Transplant-lite: induction of graft-vs-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 16:1998;2817-2824.
3. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 91:1998;756-763.
4. Spitzer T.R., McAfee S., Sackstein R., et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant. 6:2000;309-320.
5. Andreani M., Manna M., Lucarelli G., et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood. 87:1996;3494-3499.
6. Andreani M., Nesci S., Lucarelli G., et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant. 25:2000;401-404.
7. Aiuti A., Slavin S., Aker M., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 296:2002;2410-2413.
8. Walters M.C., Patience M., Leisenring W., et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 7:2001;665-673.
9. Najfeld V., Burnett W., Vlachos A., et al. Interphase FISH analysis of sex-mismatched BMT utilizing dual color XY probes. Bone Marrow Transplant. 19:1997;829-834.
10. Oberkircher A.R., Strout M.P., Herzig G.P., et al. Description of an efficient and highly informative method for the evaluation of hematopoietic chimerism following allogeneic bone marrow transplantation. Bone Marrow Transplant. 16:1995;695-702.
11. Ugozzoli L., Yam P., Petz L.D., et al. Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation. Blood. 77:1991;1607-1615.
12. Lawler M., Humphries P., McCann S.R. Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction. Blood. 77:1991;2504-2514.
13. Shimoni A., Nagler A., Kaplinsky C., et al. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the BioView (Duet) combined morphological and cytogenetical analysis. Leukemia. 16:2002;1413-1418. discussion 1419-1422.
14. Alizadeh M., Bernard M., Danic B., et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood. 99:2002;4618-4625.
15. Roy D.C., Tantravahi R., Murray C., et al. Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood. 75:1990;296-304.
16. Ginsburg D., Antin J.H., Smith B.R., et al. Origin of cell populations after bone marrow transplantation. Analysis using DNA sequence polymorphisms. J Clin Invest. 75:1985;596-603.
17. Oliver D.H., Thompson R.E., Griffin C.A., et al. Use of single nucleotide polymorphisms (SNP) and real-time polymerase chain reaction for bone marrow engraftment analysis. J Mol Diagn. 2:2000;202-208.
18. Scharf S.J., Smith A.G., Hansen J.A., et al. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood. 85:1995;1954-1963.
19. Auffermann-Gretzinger S., Lossos I.S., Vayntrub T.A., et al. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood. 99:2002;1442-1448.
20. Dubovsky J., Daxberger H., Fritsch G., et al. Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. Leukemia. 13:(2059):1999;2059-2069.
21. McSweeney P.A., Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant. 5:1999;192-203.
22. Schwartz E., Benz E.J., Forget B.G. Thalassemia syndromes. Hoffman R., Benz E.J., Shahil J.J., et al. Hematology: Basic Principles and Practice. 1995;586-610 Churchill Livingstone, New York.
23. Hochberg E.P., Miklos D.B., Neuberg D., et al. A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. Blood. 101:2003;363-369.
24. Wang D.G., Fan J.B., Siao C.J., et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science. 280:1998;1077-1082.
25. Cargill M., Altshuler D., Ireland J., et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 22:1999;231-238.
26. Brookes A.J., Lehvaslaiho H., Siegfried M., et al. HGBASE: a database of SNPs and other variations in and around human genes. Nucleic Acids Res. 28:2000;356-360.
27. Kean L.S., Durham M.M., Adams A.B., et al. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood. 99:2002;1840-1849.
28. Iannone R., Luznik L., Engstrom L.W., et al. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia. Blood. 97:2001;3960-3965.
29. Marks D.I., Lush R., Cavenagh J., et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 100:2002;3108-3114.
30. Baron F., Dresse M.F., Beguin Y. Donor lymphocyte infusion to eradicate recurrent host hematopoiesis after allogeneic BMT for sickle cell disease. Transfusion. 40:2000;1071-1073.
31. Bellucci R., Alyea E.P., Weller E., et al. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood. 99:2002;4610-4617.
32. Orsini E., Alyea E.P., Chillemi A., et al. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant. 6:2000;375-386.